Expert Interview
A Third Look: Discussing the results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist in development by Genentech/Roche as a once-weekly subcutaneous injection for the treatment of obesity and type 2 diabetes.
Ticker(s): RHHBYInstitution: Glandt Center for Diabetes
- Treats 40 patients with type-2 diabetes per week
- Founder of the Glandt Center for Diabetes
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
